Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid-free versus steroid-based immunosuppression to reduce new-onset diabetes after kidney transplantation
2012-000451-13Phase 4Completed
- Sponsor
- National Kidney and Transplant Institute
- Start
- Jun 2012
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin rabbit, basiliximab, tacrolimus, mycophenolate mofetil and corticosteroids in kidney transplant immunosuppression (2 arms), sponsored by National Kidney and Transplant Institute. Primary endpoint: Incidence of new onset diabetes mellitus. Started Jun 2012; status: completed.
02
Drugs
antithymocyte globulin rabbitbasiliximabtacrolimusmycophenolate mofetilcorticosteroids
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2012-000451-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000451-13.